{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:17:52Z","timestamp":1778566672975,"version":"3.51.4"},"reference-count":193,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitor (ICI) based combination therapies have revolutionized the management of advanced clear-cell renal cell carcinoma (ccRCC), establishing a new standard of care and significantly improving survival outcomes. However, this success is challenged by substantial heterogeneity in patient response, with primary and acquired resistance remaining major clinical hurdles that limit durable benefit for a substantial proportion of patients. This review synthesizes our current understanding of the multifaceted mechanisms governing these outcomes. We explore the complex interplay between tumor-intrinsic drivers of resistance, such as mutations in key genes like PBRM1, and the profoundly immunosuppressive landscape of the tumor microenvironment (TME), which includes diverse inhibitory cell populations, metabolic reprogramming, and stromal barriers. We then highlight how multi-omics technologies, from single-cell and spatial transcriptomics to proteomics, are decoding the TME\u2019s intricate cellular and spatial architecture to reveal novel biomarkers and therapeutic targets. Crucially, we discuss the pivotal role of artificial intelligence (AI) in translating this high dimensional data into clinically actionable insights. AI-driven models in pathomics and radiomics are creating powerful, non-invasive tools to predict treatment response and prognosis from images, while deep learning algorithms are proving essential for integrating multi-omics data to guide patient selection and accelerate drug discovery. Ultimately, the convergence of these advanced biological insights and computational strategies is paving the way for precision immuno-oncology, with the goal of moving beyond current risk stratification toward truly personalized ICI therapy for patients with ccRCC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1774959","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:44:02Z","timestamp":1778564642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Deciphering the mechanistic landscape of immune checkpoint blockade in ccRCC: from molecular drivers to therapeutic responses"],"prefix":"10.3389","volume":"17","author":[{"given":"Lingxiang","family":"Ran","sequence":"first","affiliation":[{"name":"Department of Urology, The First People\u2019s Hospital of Hefei","place":["Hefei, China"]},{"name":"Department of Urology, Peking University First Hospital","place":["Beijing, China"]},{"name":"Department of Urology, The Second Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangmo","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First People\u2019s Hospital of Hefei","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Fan","sequence":"additional","affiliation":[{"name":"West China Biomedical Big Data Center, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyin","family":"Teng","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Acupuncture Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The First People\u2019s Hospital of Hefei","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Min","family":"Yang","sequence":"additional","affiliation":[{"name":"West China Biomedical Big Data Center, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First People\u2019s Hospital of Hefei","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Bray","year":""},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","author":"Siegel","year":""},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0211-5","article-title":"The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications","volume":"16","author":"Linehan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3233\/KCA-210012","article-title":"A systematic review of immune checkpoint inhibitors in non-clear-cell renal cancer","volume":"6","author":"Palma Dos Reis","year":"2022","journal-title":"KCA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"key":"B7","article-title":"Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment","volume":"39","author":"Bahadoram","year":"2022","journal-title":"G Ital Nefrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European association of urology guidelines on renal cell carcinoma: The 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004803","article-title":"Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood","volume":"10","author":"Carlisle","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.184545","article-title":"Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti\u2013CTLA-4 in renal cell carcinoma","volume":"10","author":"Schoenfeld","year":"2025","journal-title":"JCI Insight"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41388-025-03289-0","article-title":"LRRK2 reduces the sensitivity to TKI and PD-1 blockade in ccRCC via activating LPCAT1","author":"Hong","year":"2025","journal-title":"Oncogene"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03198-8","article-title":"PTPRZ1 dephosphorylates and stabilizes RNF26 to reduce the efficacy of TKIs and PD-1 blockade in ccRCC","volume":"43","author":"Ma","year":"2024","journal-title":"Oncogene"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.89","article-title":"Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma","volume":"6","author":"Sweeney","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115389","article-title":"Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A european multicenter study (LENVA-LAT)","volume":"220","author":"Gavira","year":"2025","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2276629","article-title":"Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma","volume":"19","author":"Jang","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102235","article-title":"High sensitivity circulating tumor-DNA assays in renal cell carcinoma\u2013Are we there yet","volume":"22","author":"Sidhom","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00773","article-title":"Adjuvant nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: Part B of the randomized, placebo-controlled, phase III CheckMate 914 trial","author":"Motzer","year":"2025","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010059","article-title":"Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma","volume":"13","author":"Maritaz","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123159","article-title":"Biological biomarkers of response and resistance to immune checkpoint inhibitors in renal cell carcinoma","volume":"15","author":"Masson","year":"2023","journal-title":"Cancers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00942-1","article-title":"Biomarker-informed care for patients with renal cell carcinoma","volume":"6","author":"McKinnon","year":"2025","journal-title":"Nat Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003231","article-title":"Immuno-oncology trends: Preclinical models, biomarkers, and clinical development","volume":"10","author":"Franklin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008368","article-title":"NKG2A(+)CD8(+) T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma","volume":"12","author":"Qiu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00676-0","article-title":"Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma","volume":"20","author":"Rosellini","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-4849400\/v1","article-title":"Neoadjuvant cabozantinib restores CD8 T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: A phase 2 trial","volume-title":"In ftrgsdexreview","author":"Kissick","year":"2024"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.04.001","article-title":"Management of metastatic renal cell carcinoma: Guideline updates","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol Focus"},{"key":"B27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: A systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: Results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet (lond Engl)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010183","article-title":"Spatial and single-cell transcriptomics reveal cellular heterogeneity and a novel cancer-promoting treg cell subset in human clear-cell renal cell carcinoma","volume":"13","author":"Song","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s12672-024-01437-8","article-title":"Application of artificial intelligence model in pathological staging and prognosis of clear cell renal cell carcinoma","volume":"15","author":"Yao","year":"2024","journal-title":"Discov Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02010","article-title":"Artificial intelligence\u2013powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non\u2013small-cell lung cancer","volume":"40","author":"Park","year":"2022","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-00994-0","article-title":"Artificial intelligence in cancer target identification and drug discovery","volume":"7","author":"You","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbad019","article-title":"Artificial intelligence-based non-invasive tumor segmentation, grade stratification and prognosis prediction for clear-cell renal-cell carcinoma","volume":"6","author":"Chen","year":"2023","journal-title":"Precis Clin Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13045-023-01514-5","article-title":"Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30159-X","article-title":"An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: A blinded clinical validation and deployment study","volume":"2","author":"Pantanowitz","year":"2020","journal-title":"Lancet Digit Health"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ajcp\/aqae002","article-title":"Immune checkpoint inhibitor\u2013related colitis in patients on immunotherapy for cancer","volume":"162","author":"Sun","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","article-title":"Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma","volume":"39","author":"Au","year":"2021","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2274","article-title":"PD-1 expression on intratumoral regulatory T cells is associated with lack of benefit from anti\u2013PD-1 therapy in metastatic clear-cell renal cell carcinoma patients","volume":"30","author":"Denize","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41435-024-00312-4","article-title":"GXYLT2: An emerging therapeutic target and predictive biomarker for anti-PD-1 efficacy in clear cell renal cell carcinoma","volume":"26","author":"Guo","year":"2025","journal-title":"Genes Immun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114725","article-title":"Dual cytokine-engineered macrophages rejuvenate the tumor microenvironment and enhance anti-PD-1 therapy in renal cell carcinoma","volume":"156","author":"Liu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001506","article-title":"Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC","volume":"9","author":"Ross-Macdonald","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102921","article-title":"An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC)","volume":"149","author":"D'Angelo","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.990367","article-title":"Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance","volume":"12","author":"Schoenfeld","year":"2022","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall survival and response with nivolumab and relatlimab in advanced melanoma","volume":"2","author":"Long","year":"2023","journal-title":"NEJM Evidence"},{"key":"B49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.910388","article-title":"Correlation of T cell immunoglobulin and ITIM domain (TIGIT) and programmed death 1 (PD-1) with clinicopathological characteristics of renal cell carcinoma may indicate potential targets for treatment","volume":"24","author":"Hong","year":"2018","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25777","article-title":"Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma","volume":"56","author":"Li","year":"2012","journal-title":"Hepatol (Baltim Md)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4149\/neo_2014_006","article-title":"Prognostic implication of TIM-3 in clear cell renal cell carcinoma","volume":"61","author":"Yuan","year":"2014","journal-title":"Neoplasma"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0218","article-title":"The future of immunotherapy in advanced renal cell carcinoma: Beyond PD-1\/PD-L1 inhibitors","volume":"15","author":"Nuvola","year":"2023","journal-title":"Immunotherapy"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2018.04.001","article-title":"ILT4 functions as a potential checkpoint molecule for tumor immunotherapy","volume":"1869","author":"Gao","year":"2018","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0315","article-title":"KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1","volume":"9","author":"Bhatt","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf9792","article-title":"KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.2025.43.5_suppl.598","article-title":"Evaluating the combined role of HHLA2 and PD-L1 as biomarkers in first-line nivolumab therapy in advanced clear cell renal cell carcinoma","volume":"43","author":"Nabil Laimon","year":"2025","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s43856-025-00786-x","article-title":"Acquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal cascade","volume":"5","author":"Chung","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.010","article-title":"Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I\/II KEYMAKER-U03 trial","volume":"37","author":"Suarez","year":"2026","journal-title":"Ann Oncol"},{"key":"B61","article-title":"Monitoring tumor infiltrating lymphocytes by peripheral blood in lung cancer patients","volume":"47","author":"Muto","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00211-8","article-title":"Predictive biomarkers of anti-PD-1\/PD-L1 therapy in NSCLC","volume":"10","author":"Niu","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-023-09376-2","article-title":"Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis","volume":"71","author":"Qayoom","year":"2023","journal-title":"Immunol Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.05.003","article-title":"Treg-mediated acquired resistance to immune checkpoint inhibitors","volume":"457","author":"Saleh","year":"2019","journal-title":"Cancer Lett"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1862948","article-title":"Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma","volume":"10","author":"Kato","year":"2021","journal-title":"Oncoimmunology"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008226","article-title":"Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma","volume":"12","author":"Tian","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202402973","article-title":"Targeting hypoxia and autophagy inhibition via delivering sonodynamic nanoparticles with HIF-2\u03b1 inhibitor for enhancing immunotherapy in renal cell carcinoma","volume":"13","author":"Zhu","year":"2024","journal-title":"Adv Healthcare Mater"},{"key":"B70","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41559-021-01586-x","article-title":"Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx renal study","volume":"6","author":"Fu","year":"2022","journal-title":"Nat Ecol Evol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37060","article-title":"Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment","volume":"10","author":"Deng","year":"2024","journal-title":"Heliyon"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107986","article-title":"Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach","author":"Chamseddine","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15497","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"113","author":"Nagasaki","year":"2022","journal-title":"Cancer Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13195738","article-title":"Novel immune checkpoint inhibitor targets in advanced or metastatic renal cell carcinoma: State of the art and future perspectives","volume":"13","author":"Compagno","year":"2024","journal-title":"J Clin Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00251-y","article-title":"Metabolic reprogramming in macrophage responses","volume":"9","author":"Liu","year":"2021","journal-title":"biomark Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2019.118604","article-title":"Aerobic glycolysis is a metabolic requirement to maintain the M2-like polarization of tumor-associated macrophages","author":"de-Brito","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-022-01382-6","article-title":"Anti-angiogenesis revisited: Reshaping the treatment landscape of advanced non-small cell lung cancer","volume":"45","author":"Choi","year":"2022","journal-title":"Arch Pharmacal Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","author":"Patel","year":"2022","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3034","article-title":"Mesenchymal-like tumor cells and myofibroblastic cancer-associated fibroblasts are associated with progression and immunotherapy response of clear cell renal cell carcinoma","volume":"83","author":"Davidson","year":"2023","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-023-01824-9","article-title":"Extracellular vesicle-circEHD2 promotes the progression of renal cell carcinoma by activating cancer-associated fibroblasts","volume":"22","author":"He","year":"2023","journal-title":"Mol Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"B84","doi-asserted-by":"publisher","first-page":"OP","DOI":"10.1200\/OP-24-00875","article-title":"Recent developments in the management of renal cell cancer","author":"Chen","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"B85","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41581-025-00983-w","article-title":"Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors","volume":"21","author":"Burgers","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s44318-024-00262-7","article-title":"Alternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer","volume":"43","author":"Cho","year":"2024","journal-title":"EMBO J"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1066347","article-title":"PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers","volume":"13","author":"Dai","year":"2022","journal-title":"Front Genet"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412967","article-title":"CDC20-mediated selective autophagy degradation of PBRM1 affects immunotherapy for renal cell carcinoma","volume":"12","author":"Fan","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.0148","article-title":"148 PBRM1 mutation improves immunotherapy response in clear-cell renal cell carcinoma patients contingent on metabolic subtypes","volume":"12","author":"Pirhaji","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010386","article-title":"Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma","volume":"13","author":"Lu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fimmu.2024.1457691","article-title":"TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13758","article-title":"Paradoxical effect of myosteatosis on the immune checkpoint inhibitor response in metastatic renal cell carcinoma","volume":"16","author":"Yu","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B93","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-025-03293-y","article-title":"Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma","volume":"44","author":"Pourmir","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.185963","article-title":"Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy","volume":"10","author":"Hwang","year":"2025","journal-title":"JCI Insight"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35288","article-title":"Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial","volume":"156","author":"Gr\u00fcnwald","year":"2025","journal-title":"Int J Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01911-x","article-title":"Evolution of cell therapy for renal cell carcinoma","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12951-025-03170-y","article-title":"Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity","volume":"23","author":"Liu","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41467-024-55642-8","article-title":"Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: A phase 1 trial","volume":"16","author":"Msaouel","year":"2025","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0604","article-title":"Combining the tyrosine kinase inhibitor cabozantinib and the mTORC1\/2 inhibitor sapanisertib blocks ERK pathway activity and suppresses tumor growth in renal cell carcinoma","volume":"83","author":"Wu","year":"2023","journal-title":"Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-024-01880-0","article-title":"Frontier knowledge and future directions of programmed cell death in clear cell renal cell carcinoma","volume":"10","author":"Fei","year":"2024","journal-title":"Cell Death Discov"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5269","article-title":"Immune checkpoint inhibitor therapy before nephrectomy for locally advanced and metastatic renal cell carcinoma: A review","volume":"10","author":"Ghoreifi","year":"2024","journal-title":"JAMA Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.10.019","article-title":"First and second-line treatments in metastatic renal cell carcinoma","volume":"87","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.eururo.2023.02.011","article-title":"Assessing long-term treatment benefits using complementary statistical approaches: An in silico analysis of the phase III keynote-045 and checkmate-214 immune checkpoint inhibitor trials","volume":"85","author":"Cavillon","year":"2024","journal-title":"Eur Urol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.21037\/tau-23-588","article-title":"The final report of KEYNOTE-426 showed the efficacy and safety as a treatment for advanced renal cell carcinoma","volume":"13","author":"Ohba","year":"2024","journal-title":"Transl Androl Urol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1200\/JCO.2021.39.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426","volume":"39","author":"Rini","year":"2021","journal-title":"JCO"},{"key":"B109","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00262-025-04019-x","article-title":"Pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: Real-world evidences from the international ARON- 1 study","volume":"74","author":"Porta","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B110","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00262-024-03897-x","article-title":"First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: A real-world retrospective comparison from the ARON-1 study","volume":"74","author":"Roviello","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf004","article-title":"Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors","volume":"30","author":"do Amaral","year":"2025","journal-title":"Oncologist"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0017","article-title":"Immunotherapy strategies after immune checkpoint inhibitor exposure in renal cell carcinoma: A review","volume":"11","author":"Giudice","year":"2025","journal-title":"JAMA Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae182","article-title":"First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: Subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in eastern asia","volume":"55","author":"Chung","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00747-w","article-title":"Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment","volume":"20","author":"Nolla","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","article-title":"Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: An open-label, randomised, phase 3 trial","volume":"23","author":"Cella","year":"2022","journal-title":"Lancet Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1255577","article-title":"Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: A systematic review and network meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.07.016","article-title":"First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma: An international multicenter study","volume":"86","author":"El Zarif","year":"2024","journal-title":"Eur Urol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN guidelines\u00ae insights: Kidney cancer, version 2.2024","volume":"22","author":"Motzer","year":"2024","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.10.010","article-title":"The 2022 updated european association of urology guidelines on the use of adjuvant immune checkpoint inhibitor therapy for renal cell carcinoma","volume":"83","author":"Choueiri","year":"2023","journal-title":"Eur Urol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial","volume":"401","author":"Bedke","year":"2023","journal-title":"Lancet"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): A multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Motzer","year":"2022","journal-title":"Lancet"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00211-0","article-title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): An open-label, randomised, phase 3 study","volume":"25","author":"Pal","year":"2024","journal-title":"Lancet Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01161-5","article-title":"Treatment landscape of renal cell carcinoma","volume":"24","author":"Allaf","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00922-5","article-title":"Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: A phase 2 trial","volume":"6","author":"Chen","year":"2025","journal-title":"Nat Cancer"},{"key":"B132","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.euo.2024.09.002","article-title":"Neoadjuvant and adjuvant immune-based approach for renal cell carcinoma: Pros, cons, and future directions","volume":"8","author":"Marandino","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100947","article-title":"Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma","volume":"4","author":"Marandino","year":"2023","journal-title":"Cell Rep Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.024","article-title":"The significance of PARP1 as a biomarker for predicting the response to PD-L1 blockade in patients with PBRM1-mutated clear cell renal cell carcinoma","volume":"81","author":"Hagiwara","year":"2022","journal-title":"Eur Urol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Hagiwara","year":"2012","journal-title":"Nat Genet"},{"key":"B136","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41597-025-04666-w","article-title":"Single-cell assay for transposase-accessible chromatin sequencing of human clear cell renal cell carcinoma","volume":"12","author":"Pe\u00f1a-Llopis","year":"2025","journal-title":"Sci Data"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2224","article-title":"Integrative single-cell analysis reveals transcriptional and epigenetic regulatory features of clear cell renal cell carcinoma","volume":"83","author":"Motzer","year":"2023","journal-title":"Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.7150\/thno.109097","article-title":"Spatially segregated APOE+ macrophages restrict immunotherapy efficacy in clear cell renal cell carcinoma","volume":"15","author":"Lu","year":"2025","journal-title":"Theranostics"},{"key":"B139","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","article-title":"Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy","volume":"39","author":"Yu","year":"2021","journal-title":"Cancer Cell"},{"key":"B140","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Ge","year":"2021","journal-title":"Cancer Cell"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-023-00441-5","article-title":"High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints","volume":"7","author":"Krishna","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02978-9","article-title":"A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma","volume":"30","author":"Bi","year":"2024","journal-title":"Nat Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008613","article-title":"Integrated analysis of tertiary lymphoid structures and immune infiltration in ccRCC microenvironment revealed their clinical significances: A multicenter cohort study","volume":"12","author":"Raghubar","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006667","article-title":"Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma","volume":"11","author":"Kinget","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B145","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1038\/s41467-019-12361-9","article-title":"Metabolomic adaptations and correlates of survival to immune checkpoint blockade","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1846901","article-title":"Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma","volume":"9","author":"Xu","year":"2020","journal-title":"Oncoimmunology"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00818-y","article-title":"Diagnostic liquid biopsy biomarkers in renal cell cancer","volume":"21","author":"Zieren","year":"2024","journal-title":"Nat Rev Urol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-00363","article-title":"Artificial intelligence\u2013supported development of health guideline questions","volume":"177","author":"Montemagno","year":"2024","journal-title":"Ann Intern Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115367","article-title":"Development of an artificial intelligence-generated, explainable treatment recommendation system for urothelial carcinoma and renal cell carcinoma to support multidisciplinary cancer conferences","volume":"220","author":"Zieren","year":"2025","journal-title":"Eur J Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004316","article-title":"Biomarker analysis from CheckMate 214: Nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma","volume":"10","author":"Sousa-Pinto","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B151","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10555-025-10246-6","article-title":"Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: A systematic review and meta-analysis","volume":"44","author":"Duwe","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.007","article-title":"Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma","volume":"36","author":"Motzer","year":"2025","journal-title":"Ann Oncol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41467-025-56784-z","article-title":"Artificial intelligence links CT images to pathologic features and survival outcomes of renal masses","volume":"16","author":"Ezdoglian","year":"2025","journal-title":"Nat Commun"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30154-8","article-title":"Digital pathology and artificial intelligence","volume":"20","author":"Niazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0252-y","article-title":"Artificial intelligence in digital pathology \u2014 new tools for diagnosis and precision oncology","volume":"16","author":"Bera","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.10.018","article-title":"Clinical application of digital and computational pathology in renal cell carcinoma: A systematic review","volume":"7","author":"Niazi","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00805-3","article-title":"Bioinformatics in urology \u2014 molecular characterization of pathophysiology and response to treatment","volume":"21","author":"Hashemi Gheinani","year":"2024","journal-title":"Nat Rev Urol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"10.1097\/JS9.2484","DOI":"10.1097\/JS9.0000000000002484","article-title":"An artificial intelligence model for nuclear grading of clear cell renal cell carcinoma using whole slide images: A retrospective, multicentre, diagnostic study","author":"Khene","year":"","journal-title":"Int J Surg"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04489-7","article-title":"A self-supervised vision transformer to predict survival from histopathology in renal cell carcinoma","volume":"41","author":"Hashemi Gheinani","year":"2023","journal-title":"World J Urol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1038\/s41467-025-57717-6","article-title":"Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial","volume":"16","author":"Zheng","year":"2025","journal-title":"Nat Commun"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100980","article-title":"Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric study","volume":"4","author":"Wessels","year":"2023","journal-title":"Cell Rep Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00599-0","article-title":"Deep learning using histological images for gene mutation prediction in lung cancer: A multicentre retrospective study","volume":"26","author":"Jasti","year":"2025","journal-title":"Lancet Oncol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2025.112146","article-title":"Tumor grade-titude: XGBoost radiomics paves the way for RCC classification","volume":"188","author":"Niehues","year":"2025","journal-title":"Eur J Radiol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-025-01723-x","article-title":"Enhanced staging of renal cell carcinoma using tumor morphology features: Model development and multi-source validation","volume":"8","author":"Zhao","year":"2025","journal-title":"NPJ Digital Med"},{"key":"B165","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40644-025-00835-7","article-title":"Navigating advanced renal cell carcinoma in the era of artificial intelligence","volume":"25","author":"Najem","year":"2025","journal-title":"Cancer Imaging"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03334-5","article-title":"Radiomics can predict tumour response in patients treated with nivolumab for a metastatic renal cell carcinoma: An artificial intelligence concept","volume":"39","author":"Yuan","year":"2021","journal-title":"World J Urol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2172926","article-title":"Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study","volume":"19","author":"Najem","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092482","article-title":"Change in splenic volume as a surrogate marker for immunotherapy response in patients with advanced urothelial and renal cell carcinoma\u2014evaluation of a novel approach of fully automated artificial intelligence based splenic segmentation","volume":"11","author":"Khene","year":"2023","journal-title":"Biomedicines"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101719","article-title":"Radiomics in breast cancer: Current advances and future directions","volume":"5","author":"Rossi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009140","article-title":"Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction","volume":"13","author":"Duwe","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3756","article-title":"Antibody-enabled small-molecule drug discovery","volume":"11","author":"Lawson","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B172","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cbpa.2019.10.003","article-title":"Machine learning for target discovery in drug development","volume":"56","author":"Rodrigues","year":"2020","journal-title":"Curr Opin Chem Biol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103302","article-title":"High throughput screening identifies repurposable drugs for modulation of innate and acquired immune responses","volume":"148","author":"Lawson","year":"2024","journal-title":"J Autoimmun"},{"key":"B174","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.chembiol.2018.11.011","article-title":"HTiP: high-throughput immunomodulator phenotypic screening platform to reveal IAP antagonists as anti-cancer immune enhancers","volume":"26","author":"Mo","year":"2019","journal-title":"Cell Chem Biol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28500","article-title":"Discovering cancer immunotherapy targets in vivo","volume":"3","author":"Zhou","year":"2014","journal-title":"Oncoimmunology"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2019.03.004","article-title":"Discovering anti-cancer immune enhancers in a miniaturized immune-tumor microenvironment","volume":"26","author":"Huber","year":"2019","journal-title":"Cell Chem Biol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.616570","article-title":"Screening of FDA-approved drug library identifies adefovir dipivoxil as highly potent inhibitor of T cell proliferation","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.07.005","article-title":"Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling","volume":"25","author":"Zhao","year":"2020","journal-title":"Drug Discov Today"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2001950","article-title":"Network-Based Tools for the Identification of Novel Drug TargetsAdapted from the opening presentation at the International Conference on Systems Biology of Human Disease (SBHD) in Boston, Massachusetts, 16 to 18 June 2010","volume":"4","author":"Voss","year":"2011","journal-title":"Sci Signal"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.008","article-title":"Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets","volume":"184","author":"Stenzinger","year":"2021","journal-title":"Cell"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.014","article-title":"Applications of immunogenomics to cancer","volume":"168","author":"Liu","year":"2017","journal-title":"Cell"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Stenzinger","year":"2018","journal-title":"Science"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"B184","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cr.2016.155","article-title":"Immune targets and neoantigens for cancer immunotherapy and precision medicine","volume":"27","author":"Wang","year":"2017","journal-title":"Cell Res"},{"key":"B185","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41568-022-00529-3","article-title":"The coming decade in precision oncology: six riddles","volume":"23","author":"Sahin","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B186","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B188","article-title":"Generalizable AI predicts immunotherapy outcomes across cancers and treatments","volume-title":"medRxiv","author":"Keenan","year":""},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.147","article-title":"Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy","volume":"2","author":"Berger","year":"2023","journal-title":"Imeta"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2023.100487","article-title":"Deciphering \u201cthe language of nature\u201d: A transformer-based language model for deleterious mutations in proteins","volume":"4","author":"Jiang","year":"2023","journal-title":"Innovation"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0736-4","article-title":"Single-cell genomic approaches for developing the next generation of immunotherapies","volume":"26","author":"Yofe","year":"2020","journal-title":"Nat Med"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2018.02.010","article-title":"Genomics and emerging biomarkers for immunotherapy of colorectal cancer","volume":"52","author":"Kather","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0903","article-title":"Mutational landscape and sensitivity to immune checkpoint blockers","volume":"22","author":"Chabanon","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:44:04Z","timestamp":1778564644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":193,"alternative-id":["10.3389\/fimmu.2026.1774959"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1774959","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"article-number":"1774959"}}